李慧卿++宋娟
DOI:10.16662/j.cnki.1674-0742.2017.23.160
[摘要] 目的 探讨替普瑞酮联合雷贝拉唑治疗慢性胃炎的疗效。方法 方便选择该卫生队2013年1月—2016年12月收治的慢性胃炎患者78例进行分组回顾分析。随机将78例患者分为单药治疗组39例和联合治疗组39例,单药治疗组采取替普瑞酮胶囊治疗,联合治疗组在单药治疗组基础上联合雷贝拉唑钠肠溶胶囊治疗。比较:①总有效率;②治疗前后患者胃黏膜组织炎症和疼痛的评分;③药物安全性的差异。结果 ①联合治疗组的总有效率为97.4%(38/39),单药治疗组的总有效率为74.4%(29/39),联合治疗组对比单药治疗组总有效率更高,差异有统计学意义(P<0.05);②治疗前患者胃黏膜组织炎症和疼痛评分相似,差异无统计学意义(P>0.05);治疗后患者胃黏膜组织炎症和疼痛改善更显著,差异有统计学意义(P<0.05);③两组患者药物使用安全性高,均无出现严重不良的叉,差异无统计学意义(P>0.05)。结论 慢性胃炎给予替普瑞酮和雷贝拉唑联合治疗疗效确切,可减轻炎症,缓解疼痛,改善患者生活质量,且安全可靠,值得推广。
[关键词] 慢性胃炎; 雷贝拉唑; 替普瑞酮
[中图分类号] R573 [文献标识码] A [文章编号] 1674-0742(2017)08(b)-0160-03
Analysis of Curative Effect of Teprenone Combined with Rabeprazole in the Treatment of Chronic Gastritis
LI Hui-qing,SONG Juan
Shijiazhuang Public Security Fire Control Medical Team, Shijiazhuang, Hebei Province, 050013 China
[Abstracts] Objective This paper tries to study the clinical treatment and curative effect of teprenone combined with rabeprazole in the treatment of chronic gastritis. Methods 78 cases of patients with chronic gastritis treated in this hospital from January 2013 to December 2016 were conveniently selected and retrospectively analyzed and randomly divided into the single drug treatment group (39 cases, using teprenone capsule treatment) and the combined treatment group (39 cases, using teprenone combined with rabeprazole treatment). The following aspects were compared: ①the total effective rate;③patients with gastric mucosal inflammation and pain scores before and after treatment;③the difference of drug safety. Results ①the total effective rate of the combined treatment group was 97.40% (38/39), the total effective rate of the single drug treatment group was 74.40%(29/39), and the total effective rate of the combined treatment group was higher than that of the single drug treatment group(P<0.05);②the gastric mucosa tissue inflammation and pain scores with patients before treatment were similar(P>0.05); patients with gastric mucosal inflammation and pain improved more significantly after treatment(P<0.05); ③the drugs were of high safety in the two groups, with no adverse reactions(P>0.05). Conclusion The curative effect of teprenone combined with rabeprezole in the treatment of chronic gastritis is remarkable, which can reduce inflammation, relieve pain, improve patients life quality, is safe and reliable, and is worth promotion.
[Key words] Chronic gastritis; Rabeprazole; Teprenone
慢性胃炎是消化系統常见疾病,对患者生活质量会造成不良影响。慢性胃炎属于临床常见的消化疾病,该类型疾病有较高发病率,而且任何年龄均可发病,病程时间长等,随着疾病的逐渐发展,极为影响着患者的正常生活以及健康状况。目前临床上对于慢性胃炎多采取药物治疗为主。随着临床医学技术的快速发展,对于慢性胃炎采用抗生素治疗、胃粘膜保护剂治疗以及PPls抑制剂等药物均有较好临床治疗价值。……